Kornimate/medical-research-clean huggingface dataset:
esketamine combined with prf for trigeminal postherpetic neuralgia

Conditions: Postherpetic; Neuralgia, Trigeminal (Etiology)

Summary: this trial's primary objective is to compare the analgesic efficacy of esketamine in combination with pulsed radiofrequency (prf) against that of prf monotherapy in patients with trigeminal postherpetic neuralgia (tphn).

this study aims to determine whether the addition of esketamine to the prf regimen can relieve pain in tphn patients. by doing so, the research endeavors to identify a rapid, effective, and safe treatment approach for refractory tphn patients

Eligibility criteria:
inclusion criteria: 1. ages more than 18 years; 2. pain persisting for over three months following the onset of the herpes zoster skin rash; 3. lesions located in the trigeminal nerve or its branches innervated regions； 4. having an average pain score of at least 4 on a numeric rating scale (nrs, 0 = no pain, 10= worst possible pain)； 5. planned to perform ct-guided prf treatment of the gasserian ganglion(gg). exclusion criteria: 1. obstructive sleep apnoea syndrome; 2. those who receive other more invasive treatments, such as radiofrequency thermocoagulation (rft) of gg. 3. a history of systemic immune diseases, organ transplantation, or cancers; 4. a history of severe cardiopulmonary, hepatic, renal dysfunction or coagulation function disorder; 5. a history of schizophrenia, epilepsy, or myasthenia gravis, delirium; 6. comorbid hyperthyroidism or phaeochromocytoma; 7. recent history of drug abuse; 8. having contraindications to esketamine; 9. communication difficulties. 10. women who are preparing for pregnancy, in the pregnancy or lactation period.

Keywords: trigeminal postherpetic neuralgia esketamine
a clinical trial comparing torcetrapib/atorvastatin to simvastatin in subjects with high cholesterol (a5091031).

Conditions: Hyperlipidemia; Dyslipidemia; Hypercholesterolemia

Summary: the torcetrapib project was terminated on december 2, 2006 due to safety findings. cholesterol levels will be measured over six weeks in subjects being treated with two different kinds of cholesterol medications to see how the different treatments compare to one another.

for additional information please call: 1-800-718-1021

Eligibility criteria:
inclusion criteria: * eligible for statin treatment for ldl cholesterol by ncep guidelines exclusion criteria: * women who are pregnant or lactating, or planning to become pregnant. * subjects taking any drugs known to be associated with an increased risk of myositis in combination with hmg-coa reductase inhibitors. * subjects with significant liver or kidney disease or significant heart failure.
maintaining abstinence in chronic cigarette smokers - 1

Conditions: Tobacco Use Disorder

Summary: the purpose of this study is to evaluate the extended pharmacological and psychological treatment for chronic cigarette smokers.

the work adapts interventions that have been successful in the general populations, and tailors them to chronic smokers, who may have numerous previous smoking treatment failures. if successful it will: (1) make available a treatment intervention that produces hight long term abstinence rates; (2) provide information on variables that predicts success and failure in this population of smokers; (3) examine the cost-effectiveness of more intensive, longer term treatments.

Eligibility criteria:
subjects (n=400) will be men and women (50%) over the age of 18 who smoke at least 10 cigarettes per day and answers yes to the question "do you smoke within 30 minutes of arising?" inclusion criteria: -subjects are age 18 and over, currently smoking 10 or more cigarettes per day, and report a smoking history of at least 5 years in response to the question "how long have you been a regular smoker?" exclusion criteria: * history of seizure or head injury resulting in unconsciousness * any condition that might predispose to seizures (brain tumor or stroke) * a current or history of anorexia nervosa or bulimia * any disease acutely life-threatening or so severe that the patient is judged unable to comply with the protocol * use of a protease inhibitor of mao inhibitor within the last two week * current use of psychiatric drugs that would interfere with interpretation of study results, including antidepressants * treatment for alcohol dependence during the last year, or evidence of alcohol abuse so severe that the patient is judged potentially unable to comply with the protocol * patients who know they are leaving the bay area within the study period and non-english speakers will be excluded * suicidal or homicidal ideation * current major depression * history of bipolar disorder * recent (within twelve months) myocardial infarction * any other medical condition that would contraindicate use of nrt or bupropion * physical limitation so severe that participation in a program of moderate exercise is not possible * pregnancy or lactation

Keywords: smoking cessation
aicr : artificial intelligence in cardiac arrest

Conditions: Cardio Respiratory Arrest

Summary: the overall incidence of cardiorespiratory arrest in europe is estimated at 350,000 to 700,000 cases per year. survival rate is estimated at 10.7% for all rhythm disorders combined. several examples of ai application in the medical field exist. ting et al have developed a computer tool capable of diagnosing the presence of diabetic retinopathy with excellent power. in resuscitation, celi et al proposed a tool capable of predicting the need for crystalloid vascular filling during a systemic inflammatory state. in nature in 2018, komorowski demonstrated the efficacy of ai in the hemodynamic management of sepsis. in a study of the renal response to fluid challenge, zhang et al. demonstrate the effectiveness of the learning machine. objectives: determination of an algorithm capable of predicting the mortality of patients admitted to intensive care units (icu) for acr from hospitalization reports (crh). also use of the algorithm to predict the risk of recurrence of the arrest, the duration of mechanical ventilation, the appearance of sepsis, the development of organ failure, prediction of the cpc (cerebral performance category), time to obtain catecholamine withdrawal, the appearance of acute renal failure with or without the need for extra-renal purification (eer) and duration under eer, the average length of stay. this project is part of a larger, nationwide project with greater power, and includes all the data generated during hospitalization in intensive care. method: an estimated total number of patients included in this study to be between 300 and 500. the population will come from the intensive care units of nice, antibes, cannes, grasse. inclusion will be retrospective, on crh, cr of ct imaging (cerebral and thoraco-abdomino-pelvic), mri, eeg, and daily follow-up words, from 2014 to the end of 2020. after anonymisation, application of semantisation using natural language processing (nlp) methods. the data to be extracted are entered in a document written by intensive care physicians. these data will then be stored in a database. in order to meet the main objective, we will develop a computer algorithm capable of predicting mortality in the study population. this algorithm, based on a large database, can be designed using machine learning or even deep learning techniques depending on the amount of data to be processed.


Eligibility criteria:
inclusion criteria: * oca recovered from: hypoxic, ischemic, pulmonary embolism, tamponade, rhythm or conduction disorder, shockable or not, intra or extra-hospital. * cr computerized, typed in pdf format exclusion criteria: -
a study to demonstrate the bioequivalence of sitagliptin/metformin combination tablets and co-administration of sitagliptin and metformin as individual tablets (0431a-095)

Conditions: Type 2 Diabetes

Summary: a three part study to demonstrate the bioequivalence of a single dose of the final market image (fmi) of sitagliptin/metformin 50/500, 50/850 and 50/1000 mg fixed-dose combination (fdc) tablet and co-administration of corresponding doses of sitagliptin and metformin as individual tablets. subject will only participate in one part, receiving treatment a and b (part i), treatment c and d (part ii) or treatment e and f (part iii).


Eligibility criteria:
inclusion criteria: * female subjects of reproductive potential test negative for pregnancy and agree to use appropriate contraception * subject is in good health and is a non-smoker exclusion criteria: * subject has a history of neoplastic disease (cancer), stroke, chronic seizures, or major neurological disorder * subject has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases * subject is a nursing mother * subject consumes excessive amounts of alcohol or caffeine * subject has donated blood, had surgery or participated in another clinical study within the past 4 weeks
trial of two central venous catheter (cvc) flushing schemes in pediatric hematology and oncology patients

Conditions: Childhood Cancer; Aplastic Anemia; Metabolic Disorders

Summary: the purpose of this study is to determine whether flushing central venous catheters (cvcs) with normal saline once per week is not inferior to flushing with 10u/ml heparin 3 times per week, in preventing cvc occlusions.

tunneled central venous catheters (cvcs) are now used routinely in pediatric hematology and oncology patients. flushing with heparin solution is routinely recommended to prevent occlusion of long term cvcs, although the concentration of heparin used, and frequency of its use varies between centres. once weekly normal saline is also used successfully in some pediatric enters. there is little evidence to support one method over the other. the investigators have designed a randomised crossover trial to directly compare once weekly normal saline flushing with 3 times per week 10u/ml heparin flushing, to determine whether normal saline is not inferior to heparin.

Eligibility criteria:
inclusion criteria * diagnosis of any malignant or nonmalignant disease that requires a single lumen broviac or double lumen hickman-type cvc for the purpose of chemotherapy, blood product support or hematopoietic stem cell transplantation. * cvc is planned to remain in situ for 6 months from study entry exclusion criteria: * thrombophilia (e.g. factor v leiden mutation, antiphospholipid syndrome) or previous thrombosis requiring anticoagulation (e.g. enoxaparin, unfractionated heparin) * bleeding disorder (e.g. von willebrand's disease, hemophilia) * previous cvc that was removed due to any complication
preventing american indian children from becoming overweight

Conditions: Cardiovascular Diseases; Heart Diseases; Obesity

Summary: the purpose of this study is to establish an intervention to keep american indian/alaskan native (ai/an) children from becoming overweight.

background: ai/an children have overweight rates that are 18 to 30 percent higher than the general american population of children. adult obesity has early antecedents, and data show that eating and physical activity behaviors are formed and set as early as 3 years of age, through primary socialization within families. yet there are few, if any, obesity prevention programs that target children younger than 3 years of age. design narrative: this is a community-partnered randomized study to prevent early childhood overweight in ai/an children. a birth cohort of about 780 children from six indian communities born over a period 18 months will be randomized by community to either a control (3 communities) or intervention condition (3 communities). the intervention comprises a community-wide intervention coupled with individualized family counseling to improve nutrition and physical activity in infants and toddlers. nutrition goals are to increase breastfeeding initiation and sustainability, limit sugared beverages for infants and toddlers, and make healthful choices during weaning and solid food introduction. physical activity goals include promoting motor development, limiting video/tv viewing, and creating play opportunities for infants and toddlers. intervention approaches and methods used in the pilot study on which this project is based will be combined with new formative data collected at the beginning of the project to enhance the intervention's feeding and physical activity components. each component in the community-wide interventions will be collaboratively designed with the tribes, and tailored to each community's needs. trained peer counselors will deliver the family interventions, during a series of 12 cluster visits, each covering a different developmental stage of the infant/toddler.

Eligibility criteria:
inclusion criteria: * women who have had uncomplicated pregnancies * women who agree to have their child enrolled in the study and followed for 30 months * women who are not planning to leave their area within 2 years of study start exclusion criteria: * women whose children have a serious illness known to affect normal growth
the role of blood flow restriction therapy in postop rehabilitation of foot and ankle injuries

Conditions: Fracture of Foot

Summary: the purpose of the study is to determine the role of blood flow restriction (bfr) + neuromuscular electrical stimulation (nmes) in improving post-operative physical therapy and recovery after ankle fracture surgery. we expect to see improved muscle strength, less muscle wasting, and improved functional recovery after surgery when making these additions to routine post-operative (postop) physical therapy protocols.

few studies have examined bfr in patients sustaining operative foot and ankle injuries. due to the weight bearing limitations and prolonged immobilization following these injuries, patients often experience increased time away from work and delays with return to sport. these factors are responsible for the rapid muscle atrophy that occurs in the immediate post injury period because of immobility and disuse. recently, blood flow restriction (bfr) therapy has been shown to be effective in improving muscle strength and preventing atrophy when combined with low load resistance training physical therapy programs.7,8 neuromuscular electrical stimulation (nmes) is an adjunctive agent that has been show to augment the effects of bfr alone.4 the null hypothesis is that a 2 week bfr + nmes + low load resistance training program in patients age \>= 18 recovering from foot and ankle surgery will have no effect on short term (2 weeks postop) lower extremity muscle hypertrophy or atrophy, patient pain and satisfaction, or functional recovery after foot and ankle surgery.

Eligibility criteria:
inclusion criteria: * isolated, closed low-energy rotational ankle fracture without prior surgery or implants to injured area exclusion criteria: * history of deep vein thrombosis in affected extremity * history of significant cardiac disease defined as a recent stent placement in past * history of peripheral arterial disease * history of sickle cell disease * history of coagulopathy * presenting to surgery \>14 days after injury
synkir-110 for mesothelin expressing ovarian cancer, cholangiocarcinoma or mesothelioma

Conditions: Ovarian Cancer; Cholangiocarcinoma Recurrent; Mesothelioma, Malignant

Summary: this first-in-human (fih) trial is designed to assess the safety, feasibility, and potential activity of a single intravenous (iv) dose of synkir-110 administered to subjects with mesothelin-expressing advanced ovarian cancer, mesothelioma, and cholangiocarcinoma.

this is a phase 1, fih, multicenter, open-label, dose-escalation pilot study of a single iv gravity drip infusion of synkir-110 in subjects with advanced, mesothelin-expressing tumors (ovarian cancer, primary peritoneal cancer, fallopian tube cancer, cholangiocarcinoma, or mesothelioma). up to 42 subjects will be assessed to determine the safety and feasibility of treatment with synkir-110. informed consent will be obtained from subjects prior to participation in this study. the study includes an enrollment screening period (which includes pre-leukapheresis safety/eligibility and leukapheresis visits), treatment period (administration of non-myeloablative lymphodepleting chemotherapy followed by a single infusion of investigational product), and a 12-month follow-up period or until disease progression. subjects will be followed for 12 months or until confirmed disease progression, whichever occurs first, at which point they will be invited to participate in a long-term safety follow-up study. up to 6 cohorts of 3 to 6 subjects per cohort will be treated to determine the safety and feasibility of treatment with synkir-110. doses will be escalated following a standard 3 + 3 design until either an mtd or mfd is reached. an additional 6 to 9 subjects will be treated at the mtd/mfd to further assess safety and potential activity of synkir-110.

Eligibility criteria:
inclusion criteria: * pathologically confirmed recurrent or relapsed advanced ovarian cancer, primary peritoneal cancer, fallopian tube cancer, cholangiocarcinoma, or epithelial mesothelioma (pleural or peritoneal) after at least 1 prior line of systemic therapy for advanced disease * adult 18 years of age or older. * eastern cooperative oncology group (ecog) performance status of 0 to 1. * has at least 1 measurable lesion by irecist for ovarian cancer or cholangiocarcinoma or lesions measurable for mrecist for mesothelioma. * satisfactory blood coagulation parameters * satisfactory organ and bone marrow function exclusion criteria: * active invasive cancers other than mesothelioma, cholangiocarcinoma, and ovarian unless surgically and medically cured without evidence of recurrent disease for 5 years. * history of t or b cell malignancies or previous gene-engineered t cell therapies. * sarcomatoid/biphasic mesothelioma. * pulmonary exclusions * have acquired hereditary, congenital immunodeficiency or have recognized immunodeficiency disease * active hepatitis b, active hepatitis c, or any hiv infection at the time of screening * active autoimmune disease
predictors of adverse neonatal outcomes in intrahepatic cholestasis of pregnancy

Conditions: Intrahepatic Cholestasis of Pregnancy

Summary: many studies have attempted to find the predictors of adverse neonatal outcome in women with intrahepatic cholestasis of pregnancy(icp).serum total bile acid level exceeding 40 µmol/l has been associated with increased risk of meconium staining, low apgar scores, preterm delivery, and stillbirth.other predictors such as level of transaminases, history of cholelithiasis, and hepatitis virus infection have been studied but the results are inconclusive.a more comprehensive investigation involving multiple neonatal outcomes and a wide variety of outcome predictors is needed in order to establish guidelines for optimal timing of delivery in pregnancies complicated by icp. the aim of our study was to evaluate wide variety of predictors of adverse neonatal outcomes in a large cohort of women with icp .

we performed a retrospective cohort study of all women diagnosed with icp. pregnancy outcomes including delivery gestational age, spontaneous preterm delivery, iatrogenic preterm delivery, birth weight, mode of delivery, oligohydramnios, intrauterine growth restriction (iugr), placental abruption, preterm premature rupture of membrane (pprom), concerning fetal heart tracing, chorioamnionitis, endometritis, postpartum hemorrhage, transfusion, stillbirth, neonatal intensive care unit (nicu) admission, hyperbilirubinemia, meconium stained amniotic fluid, respiratory distress syndrome(rds) or transient tachypnea of newborn(ttn) (transient tachypnea of the newborn), and composite neonatal outcome were ascertained. a composite adverse neonatal outcome was created and defined as any of the following: nicu admission, hypoglycemia, hyperbilirubinemia, rds, ttn, mechanical ventilation use, oxygen by nasal cannula, pneumonia, and stillbirth. pprom was defined by rupture of membrane before 37 weeks gestation. concerning fetal heart tracing was defined as recurrent variable or late decelerations with moderate variability, prolonged decelerations, or category 3 tracing. providers who were caring for the women reviewed and independently characterized fetal heart tracings. since fetal heart tracings were not accessible to authors, authors accepted the providers' interpretation. for analysis of concerning fetal heart tracing, women with non-labor cesarean section were excluded. hyperbilirubinemia was defined by neonatal hyperbilirubinemia that required phototherapy. hypoglycemia was defined by neonatal hypoglycemia that required intravenous infusion. diagnosis of rds and ttn were made by the managing neonatologist and based on standard clinical guidelines.

Eligibility criteria:
inclusion criteria: * newborns were born in maternal and child health hospital of yong chuan district from january 2012 to december 2020;②all newborns' mothers diagnosed intrahepatic cholestasis of pregnancy. exclusion criteria: the newborns were born with severe congenital heart disease and deformities
continuous intravenous sufentanil infusion for postoperative pain management following tonsillectomy or adeno-tonsillectomy in children

Conditions: Sleep Breathing Disorders; Tonsillitis; Adenoid Hypertrophy

Summary: postoperative pain following tonsillectomy or adeno-tonsillectomy in children is severe and sometimes last for days. sufentanil is used by epidural route for postoperative analgesia in children. there are few reports about its use for postoperative analgesia by continuous intravenous infusion. its complications include , hypoxia, sedation, pruritus ,nausea and/or vomiting. the investigators design this protocol to test efficacy of analgesia of three different rates of continuous intravenous sufentanil infusion for postoperative pain management following coblation tonsillectomy or adeno-tonsillectomy in children. the investigators also compare incidence rate of complications for three groups.


Eligibility criteria:
inclusion criteria: * american society of anesthesiologists grade i or ii children aged 5-8 years undergoing coblation tonsillectomy or adeno-tonsillectomy as in-patient exclusion criteria: * children with a history of adverse reaction to opioids, long-term use of opioid medications, and history of chronic pain. * psychiatric illness, kidney failure, hypotension, atrioventricular block, myasthenia gravis etc.